Data from EMC - Curated by EPG Health - Last updated 16 August 2016
Co-trimoxazole should only be used where, in the judgement of the physician, the benefits of treatment outweigh any possible risks; consideration should be given to the use of a single effective antibacterial agent.
The in vitro susceptibility of bacteria to antibiotics varies geographically and with time; the local situation should always be considered when selecting antibiotic therapy.
1) Treatment and prophylaxis (primary and secondary) of Pneumocytosis jiroveci (P. carinii) in adults and children.
2) Treatment and prophylaxis of toxoplasmosis, treatment of nocardiosis.
3) Treatment of urinary tract infections and acute exacerbations of chronic bronchitis, where there is bacterial evidence of sensitivity to Co-trimoxazole and good reason to prefer this combination to a single antibiotic.
4) Treatment of acute otitis media where there is good reason to prefer Co-trimoxazole to a single antibiotic.
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.
Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome (LEADERSHIP 301)
This study evaluates the effects of two doses of oral AQX-1125 on bladder pain and other urinary symptoms in subjects with interstitial cystitis/bladder pain syndrome.
Added 9 months ago
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)
The purpose of this study is to demonstrate the superiority of CHF 5993 pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) over Symbicort® Turbuhaler®...
Added 10 days ago
Study to Patients With Stable COPD to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate (DUAKLIR) (AVANT)
This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components...
Added 10 days ago
A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
This is a randomised, controlled, two period cross-over, 4 weeks chronic dosing, study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) and Glycopyrronium/Formoterol Fumarate (GFF)
Added 11 days ago
The aim of the present study is to evaluate the superiority of the fixed triple therapy with BDP/FF/GB at a daily dose of 400/24/50 mcg respectively with that of Ultibro® Breezhaler® (DPI)...
Added 11 months ago
Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
The rise in resistant Gram-negative bacteria is a major concern and has led to difficulty in treating multidrug-resistant (MDR) infections....
Added 3 years ago
Clinical presentation and risk factors of serious infections in children with Down syndrome treated for acute lymphoblastic leukemia.
Treatment of acute lymphoblastic leukemia (ALL) in children with Down syndrome (DS) is associated with a higher incidence of life-threatening infections compared to the overall pediatric population.
Added 2 years ago
BACKGROUND: Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal disease in infants, but their efficacy against pneumococcal community-acquired pneumonia in adults 65...
Added 4 years ago
The European Association of Urology (EAU) Urological Infections Guidelines Panel has compiled these clinical guidelines to provide medical professionals with evidence-based information and recommendations for...
Added 3 years ago
It provides evidence-based recommendations for the most common management questions occurring in routine clinical practice in the management of adult patients with LRTI.
Added 7 years ago
|Marketing authorisation holder||Actavis UK Limited|